Quest PharmaTech Inc.
Other OTCTotal Valuation
Quest PharmaTech Inc. carries a market capitalization of 3.38M, placing it among publicly traded companies globally. Its enterprise value stands at 4.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.38M |
| Enterprise Value | 4.05M |
Share Statistics
Quest PharmaTech Inc. currently has 169.13M shares outstanding.
| Shares Outstanding | 169.13M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Quest PharmaTech Inc. trades at a trailing price-to-earnings ratio of 0.34.
| PE Ratio | 0.34 |
| PS Ratio | N/A |
| PB Ratio | 0.10 |
| P/TBV Ratio | 0.14 |
| P/FCF Ratio | -6.95 |
| P/OCF Ratio | -6.95 |
Financial Position
Quest PharmaTech Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.53, indicating elevated leverage, while an interest coverage ratio of -37.82 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.07 |
| Quick Ratio | 0.06 |
| Debt / Equity | 4.53 |
| Debt / EBITDA | -1.22 |
| Interest Coverage | -37.82 |
Financial Efficiency
| Return on Equity (ROE) | -1.18 |
| Return on Assets (ROA) | -1.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 70.88 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Quest PharmaTech Inc.'s stock has gained approximately 50.37594% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | 50.37594% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -819,145.00, while operating income came in at -819,145.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -819,145.00 |
| Pretax Income | -244,655.00 |
| Net Income | -244,655.00 |
| EBITDA | -819,145.00 |
| EBIT | -819,145.00 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Quest PharmaTech Inc. holds 59,096.00 in cash and equivalents against 1.00M in total debt, resulting in a net debt position of 940,904.00. Total book value stands at 30.59M, with working capital of -990,172.00 providing operational flexibility.
| Cash & Cash Equivalents | 59,096.00 |
| Total Debt | 1.00M |
| Net Debt | 940,904.00 |
| Equity (Book Value) | 30.59M |
| Book Value Per Share | 0.18 |
| Working Capital | -990,172.00 |
Cash Flow
Quest PharmaTech Inc. produced -446,879.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -446,879.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -446,879.00 |
| FCF Per Share | 0.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -14.40 |
Scores
Quest PharmaTech Inc. posts an Altman Z-Score of 1.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.56 |